Vektor told about plans for clinical trials of a vaccine against COVID-19 in children

"The first clinical trial of a vaccine is being carried out on children aged 14 to 17 years," Maksyutov was quoted as saying by TASS.

He said that "if it goes well, then they pass to the next age - with a decrease."

"And so six clinical trials [will pass] sequentially until we reach infants under 6 months of age," added the director of the center.

Earlier in the center "Vector" said that mass vaccination with the drug "EpiVacCorona" will start in 2021.

They noted that the existing equipment will produce up to 5 million doses of vaccine annually, but the volume may be increased. 

As emphasized in the Kremlin, the process will be phased - taking into account the geography of the country and "the peculiarities of the storage of substances."

Deputy of the State Duma of the III-V convocations, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, Honored Scientist of Russia Sergei Kolesnikov, in an interview with the FAN, recalled the features of the coronavirus.